Download PDF
Senologie - Zeitschrift für Mammadiagnostik und -therapie 2015; 12(04): 192-200
DOI: 10.1055/s-0041-108769
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Die richtige Therapie für die richtige Patientin – personalisierte Behandlung des Mammakarzinoms

The right treatment for the right patient – personalised treatment of breast cancer
A. Scharl
1   Frauenklinik, Klinikum St. Marien Amberg, Amberg
,
T. Kühn
2   Frauenklinik, Klinikum Esslingen, Esslingen
,
T. Papathemelis
1   Frauenklinik, Klinikum St. Marien Amberg, Amberg
,
A. Salterberg
3   Abteilung für Frauenheilkunde und Geburtshilfe, Sana Kliniken des Landkreises Cham, Cham
› Author Affiliations
Further Information

Publication History

Publication Date:
22 December 2015 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Heilungswahrscheinlichkeit des Mammakarzinoms wurde in den letzten Jahrzehnten durch Einführung und Optimierung multimodaler Therapien und interdisziplinäre Behandlung stark verbessert. Heutzutage erhalten die meisten Patientinnen neben der Operation eine Bestrahlung und systemische Therapie. Um eine Übertherapie zu vermeiden müssen diejenigen Patientinnen besser identifiziert werden, die eine so gute Prognose haben, dass auf manche begleitende Therapie verzichtet oder reduziert werden kann. Ein weiteres Problem ist die oft mangelnde Therapietreue (Compliance) v. a. im Bereich der jahrelangen endokrinen Therapien. Da nur eine Behandlung, die auch durchgeführt wird, das Überleben verbessern kann, müssen die Bemühungen zur Verbesserung der Compliance intensiviert werden. Studien zeigen, dass Änderungen des Lebensstils einerseits die Wirksamkeit von Medikamenten beeinflussen und andererseits auch alleine relevante Verbesserungen der Prognose bewirken können. Daher ist es an der Zeit, nicht nur den Tumor, sondern die ganze Patientin in den Mittelpunkt der therapeutischen Interventionen zu stellen.

Abstract

The probability of healing breast cancer has been greatly improved in recent decades through the introduction and optimisation of multi-modal therapies and interdisciplinary treatments. Today, in addition to surgery or radiation, most patients receive a systemic treatment. To prevent excessive treatment, patients whose prognosis is so good that certain adjuvant therapies can be foregone or reduced must be identified. A lack of compliance with therapy, especially in the endocrine therapies stretching over years, is a further problem. As only treatments that are also carried out can improve chances of survival, efforts to improve compliance must be intensified. Studies show that lifestyle changes influence the efficiency of medication on the one hand, and on the other hand can also by themselves achieve a relevant improvement of the prognosis. Therefore, it is time not only to treat the tumour, but to also focus on the patient as a whole in therapeutic interventions.

Schlüsselwörter

Brustkrebs - Lifestyle-Veränderungen - Compliance - Übertherapie - Überdiagnostik

Key words

breast cancer - lifestyle changes - compliance - excessive treatment - over-diagnosis
 

  • Literatur

  • 1 Cancerresearch UK. Age-standardised mortality rates, females, UK, 1971–2012. Online: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/mortality/uk-breast-cancer-mortality-statistics%23trends Stand: 02.03.2015
    PubMedGoogle Scholar
  • 2 SEER Databank. Online: http://seer.cancer.gov/statfacts/html/breast.html Stand: 02.03.2015
    PubMedGoogle Scholar
  • 3 Robert Koch-Institut. Gesundheitsberichterstattung des Bundes, Heft 25, Brustkrebs. 2012. Online: http://www.rki.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2012 / kid_2012_c50.pdf?__blob=publicationFile Stand: 05.11.2013
    PubMedGoogle Scholar
  • 4 Robert Koch-Institut Online: http://www.rki.de/Krebs/DE/Content/ZfKD/Aktuelles/Brustkrebsmortalitaet.html Stand: 02.03.2015
    PubMed
  • 5 Scharl A. Mammographiescreening. Gynäkologe 2014; 5: 325-333
    PubMedGoogle Scholar
  • 6 Scharl A, Costa SD. Diagnostik und Therapie des duktalen Carcinoma in situ. Gynäkol Prax 2004; 28: 61-79
    PubMedGoogle Scholar
  • 7 Liedtke C, Thill M, Hanf V et al. AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2014. Breast Care (Basel) 2014; 9: 189-200
    CrossrefPubMedGoogle Scholar
  • 8 AGO Kommission Mamma. Diagnostik und Therapie von Patientinnen mit primärem und metastasierten Brustkrebs. Online: http://www.ago-online.de/de/infothek-fuer-aerzte/leitlinienempfehlungen/mamma/ Stand: 02.03.2015
    PubMedGoogle Scholar
  • 9 Dunne C, Burke JP, Morrow M et al. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol 2009; 27: 1615-1620
    CrossrefPubMedGoogle Scholar
  • 10 Onkologisches Leitlinienprogramm. Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. 2012. Online: http://leitlinienprogramm-onkologie.de/Mammakarzinom.67.0.html Stand: 02.03.2015
    PubMedGoogle Scholar
  • 11 Kurian AW, Lichtensztajn DY, Keegan TH et al. Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998–2011. JAMA 2014; 312: 902-914
    CrossrefPubMedGoogle Scholar
  • 12 Garcia-Etienne CA, Tomatis M, Heil J et al. eusomaDB Working Group. Mastectomy trends for early-stage breast cancer: a report from the EUSOMA multi-institutional European database. Eur J Cancer 2012; 48: 1947-1956
    CrossrefPubMedGoogle Scholar
  • 13 Pilewskie M, Ho A, Orell E et al. Effect of margin width on local recurrence in triple-negative breast cancer patients treated with breast-conserving therapy. Ann Surg Oncol 2014; 21: 1209-1214
    CrossrefPubMedGoogle Scholar
  • 14 Moran MS, Schnitt SJ, Giuliano AE et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol 2014; 32: 1507-1515
    CrossrefPubMedGoogle Scholar
  • 15 Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 2010; (11) CD002748
    PubMedGoogle Scholar
  • 16 Scharl A, Salterberg A. Multimodale Therapie des nicht metastasierten Mammakarzinoms. Onkologe 2014; 4: 379-394
    PubMedGoogle Scholar
  • 17 Houssami N, Turner R, Morrow M. Preoperative magnetic resonance imaging in breast cancer. Meta-analysis of surgical outcomes. Ann Surg 2013; 257: 249-255
    CrossrefPubMedGoogle Scholar
  • 18 Houssami N, Turner R, Macaskill P et al. An individual person data meta-analysis of preoperative magnetic resonance imaging and breast cancer recurrence. J Clin Oncol 2014; 32: 392-401
    CrossrefPubMedGoogle Scholar
  • 19 Brennan ME, Houssami N. Evaluation of the evidence on staging imaging for detection of asymptomatic distant metastases in newly diagnosed breast cancer. Breast 2012; 21: 112-123
    CrossrefPubMedGoogle Scholar
  • 20 Gerber B, Seitz E, Müller H et al. Perioperative screening for metastatic disease is not indicated in patients with primary breast cancer and no clinical signs of tumor spread. Breast Cancer Res Treat 2003; 82: 29-37
    CrossrefPubMedGoogle Scholar
  • 21 Schnipper LE, Smith TJ, Raghavan D et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol 2012; 30: 1715-1724
    CrossrefPubMedGoogle Scholar
  • 22 Simos D, Hutton B, Clemons M. Are physicians choosing wisely when imaging for distant metastases in women with operable breast cancer?. J Oncol Pract 2014; pii: JOP.2014.000125 [Epub ahead of print]
    PubMedGoogle Scholar
  • 23 Davies C, Godwin J, Gray R et al. Early Breast Cancer Trialistsʼ Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771-784
    CrossrefPubMedGoogle Scholar
  • 24 Hadji P, Ziller V, Kyvernitakis J et al. Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis. Breast Cancer Res Treat 2013; 138: 185-191
    CrossrefPubMedGoogle Scholar
  • 25 Hershman DL, Shao T, Kushi LH et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011; 126: 529-537
    CrossrefPubMedGoogle Scholar
  • 26 Kidwell KM, Harte SE, Hayes DF et al. Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy. Cancer 2014; 120: 2403-2411
    CrossrefPubMedGoogle Scholar
  • 27 Irwin ML, Cartmel B, Gross CP et al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol 2014; pii: JCO.2014.57.1547 [Epub ahead of print]
    PubMedGoogle Scholar
  • 28 Fellowes D, Fallowfield LJ, Saunders CM et al. Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for ‘well-tolerated’ treatments?. Breast Cancer Res Treat 2001; 66: 73-81
    CrossrefPubMedGoogle Scholar
  • 29 Cuzick J, Sestak I, Forbes JF et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2014; 383: 1041-1048
    CrossrefPubMedGoogle Scholar
  • 30 Francis PA, Regan MM, Fleming GF et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015; 372: 436-446
    CrossrefPubMedGoogle Scholar
  • 31 Pagani O, Regan MM, Walley BA et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371: 107-118
    CrossrefPubMedGoogle Scholar
  • 32 Peto R, Davies C, Godwin J et al. Early Breast Cancer Trialistsʼ Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012; 379: 432-444
    CrossrefPubMedGoogle Scholar
  • 33 Tolaney SM, Barry WT, Dang CT et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 2015; 372: 134-141
    CrossrefPubMedGoogle Scholar
  • 34 Denkert C, von Minckwitz G, Brase JC et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol 2014; pii: JCO.2014.58.1967 [Epub ahead of print]
    PubMedGoogle Scholar
  • 35 von Minckwitz G, Hahnen E, Fasching PA et al. Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto. J Clin Oncol 2014; 32: 5 (Suppl. Abstr. 1005)
    CrossrefPubMedGoogle Scholar
  • 36 Correa C, McGale P, Taylor C et al. Early Breast Cancer Trialistsʼ Collaborative Group (EBCTCG). Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010; 2010: 162-177
    CrossrefPubMedGoogle Scholar
  • 37 Wapnir IL, Dignam JJ, Fisher B et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 2011; 103: 478-488
    CrossrefPubMedGoogle Scholar
  • 38 Deutsches Mammographiescreeningprogramm. Evaluationsbericht 2011; Online: http://fachservice.mammo-programm.de/download/Evaluationsbericht_2011_Zusammenfassung_der_Ergebnisse.pdf; Stand: 03.04.2015
    PubMedGoogle Scholar
  • 39 Darby S, McGale P, Correa C et al. Early Breast Cancer Trialistsʼ Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011; 378: 1707-1716
    CrossrefPubMedGoogle Scholar
  • 40 Schonberg MA, Marcantonio ER, Ngo L et al. Causes of death and relative survival of older women after a breast cancer diagnosis. J Clin Oncol 2011; 29: 1570-1577
    CrossrefPubMedGoogle Scholar
  • 41 Hughes KS, Schnaper LA, Bellon JR et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 2013; 31: 2382-2387
    CrossrefPubMedGoogle Scholar
  • 42 Kunkler IH, Williams LJ, Jack WJ et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol 2015; 16: 266-273
    CrossrefPubMedGoogle Scholar
  • 43 von Minckwitz G, Reimer T, Potenberg J et al. The phase III ICE study: adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. San Antonio Breast Cancer Symposium 2014; Abstr. S3-04.
    PubMedGoogle Scholar
  • 44 Online: https://www.adjuvantonline.com Stand: 02.03.2015
    PubMed
  • 45 Diel IJ, Solomayer EF, Costa SD et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357-363
    CrossrefPubMedGoogle Scholar
  • 46 Coleman R, Gnant M, Paterson A et al. Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: a meta-analysis of individual patient data from randomized trials. San Antonio Breast Cancer Symposium 2013; Abstr. S4-07.
    PubMedGoogle Scholar
  • 47 Rack B, Andergassen U, Neugebauer J et al. The German SUCCESS C Study – The first European lifestyle study on breast cancer. Breast Care (Basel) 2010; 5: 395-400
    PubMedGoogle Scholar
  • 48 Goodwin PJ. Obesity and endocrine therapy: host factors and breast cancer outcome. Breast 2013; 22 (Suppl. 02) S44-S47
    PubMedGoogle Scholar
  • 49 Chlebowski RT. Nutrition and physical activity influence on breast cancer incidence and outcome. Breast 2013; 22 (Suppl. 02) S30-S37
    PubMedGoogle Scholar
  • 50 Chlebowski RT, Blackburn GL, Thomson GA et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Womenʼs Intervention Nutrition Study (WINS). J Natl Cancer Inst 2006; 98: 1767-1776
    CrossrefPubMedGoogle Scholar
  • 51 Chlebowski RT, Blackburn GL. Final survival analysis from the randomized Womenʼs Intervention Nutrition Study (WINS) evaluating dietary intervention as adjuvant breast cancer therapy. San Antonio Breast Cancer Symposium 2014; Abstr. S5-08.
    PubMedGoogle Scholar